PRFX - צמיחת מכירות משנה לשנה (TTM) PainReform Corp

Drug delivery method patents create significant barriers for competitors, as evidenced by the TTM 12-month year-over-year revenue change, where the metric level stands at 0.00. Surgeon loyalty to PRF-110 strengthens the image of PainReform Ltd. (PRFX), although FDA approval risks and PLFE commercialization costs remain significant factors for investors.

PainReform Ltd. operates in the high-risk anesthetic development sector, where commercial success is constrained by fierce competition and a shortage of funding for final trials. This indicator measures the relative change in revenue over a rolling twelve-month period, allowing investors to assess product demand and business predictability through the dynamics of TTM revenue growth rates compared to the previous year.